---
layout: post
title: New Drug Approvals 2012 - Pt. XVI - Aclidinium bromide (TudorzaTM PressairTM)
date: '2012-07-27T09:21:00.002+01:00'
author: Rita
tags:
- Small Molecule Drugs
- 2012 New Drugs
modified_time: '2012-07-31T09:57:39.305+01:00'
thumbnail: http://4.bp.blogspot.com/-cfzGh2wvb8U/UA6oRjdVc_I/AAAAAAAAA0o/A4HhHjUoj48/s72-c/aclidinum_bromide.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8553687031127455362
blogger_orig_url: http://chembl.blogspot.com/2012/07/new-drug-approvals-2012-pt-xvi.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://www.empr.com/webservice/ImageResizer.ashx?n=http://media.empr.com/images/2012/07/24/tudorza_279921_279922.jpg&amp;h=155&amp;w=200&amp;c=0" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="155" src="http://www.empr.com/webservice/ImageResizer.ashx?n=http://media.empr.com/images/2012/07/24/tudorza_279921_279922.jpg&amp;h=155&amp;w=200&amp;c=0" width="200" /></a></div>
<br />
<br />
<br />
<center face="arial">
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,0,0,1,1,0,0" width="400" /></center>
<br />
<br />
<div style="text-align: center;">
<b>ATC Code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=R03BB05">R03BB05</a><br />
<b>Wikipedia:</b> <a href="http://en.wikipedia.org/wiki/Aclidinium">Aclidinium bromide</a><br />
<br /></div>
<div style="text-align: justify;">
On July 23<sup>th</sup>, the FDA approved Aclidinum bromide (Tradename: <a href="http://www.trademarkia.com/tudorza-85244857.html">Tudorza</a>&nbsp;<a href="http://www.trademarkia.com/tudorza-85244857.html">Pressair</a><sup>TM</sup>; Research Codes: LAS-34273, LAS W-330), a  <a href="http://en.wikipedia.org/wiki/Muscarinic_acetylcholine_receptor_M3">muscarinic acetylcholine </a><a href="http://en.wikipedia.org/wiki/Muscarinic_acetylcholine_receptor_M3">M<sub>3 </sub></a><a href="http://en.wikipedia.org/wiki/Muscarinic_acetylcholine_receptor_M3">receptor</a> antagonist, for the long-term maintenance treatment of <a href="http://en.wikipedia.org/wiki/Bronchospasm">bronchospasm</a> associated with <a href="http://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease">chronic obstructive pulmonary disease (COPD)</a>.</div>
<div style="text-align: justify;">
<br />
Chronic obstructive pulmonary disease (COPD) is characterised by the occurrence of <a href="http://en.wikipedia.org/wiki/Chronic_bronchitis">chronic bronchitis</a> or <a href="http://en.wikipedia.org/wiki/Emphysema">emphysema</a>, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. Bronchial spasms, a sudden constriction of the muscles in the walls of the <a href="http://en.wikipedia.org/wiki/Bronchiole" title="Bronchiole">bronchioles</a>, occur frequently in COPD.<br />
<br />
Aclidinum bromide is a long-acting antimuscarinic agent that through the inhibition of the muscarinic acetylcholine M<sub>3</sub> receptors present in the airway smooth muscle, leads to bronchodilation, and consequently eases the symptoms of COPD.</div>
<br />
<div style="text-align: justify;">
The muscarinic acetylcholine M<sub>3 </sub>receptor&nbsp;(Uniprot: <a href="http://www.uniprot.org/uniprot/P20309">P20309</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/index.php/target/inspect/CHEMBL245">CHEMBL245</a>) belongs to the G-protein coupled receptor (GPCR) type 1 family, and binds the endogenous neurotransmitter <a href="http://en.wikipedia.org/wiki/Acetylcholine">acethylcoline</a>. Since it is coupled to a G<sub>q</sub> protein, its inhibition leads to a decrease of intracellular calcium levels, and consequently smooth  muscle relaxation.<br />
<br />
<pre>&gt;ACM3_HUMAN Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL
</pre>
</div>
<br />
<div style="text-align: justify;">
There is one partially resolved 3D structure for this protein (<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/2csa/summary.html">2CSA</a>), but there are now several relevant homologous structures of other closely related members of the family (see <a href="http://chembl.blogspot.co.uk/p/gpcr-structures.html">here</a> for a current list of rhodopsin-like GPCR structures).<br />
<br />
The -ium USAN/INN stem covers quaternary ammonium compounds. Members of these class include for example <a href="http://en.wikipedia.org/wiki/Tiotropium_bromide">tiotropium bromide</a> (ChEMBL ID: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1182657%22">CHEMBL1182657</a>), and <a href="http://en.wikipedia.org/wiki/Ipratropium_bromide">ipratropium bromide</a> (ChEMBL ID: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1615433">CHEMBL1615433</a>, which are also anthicholinergic drugs approved for the treatment of COPD.<br />
<br /></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-cfzGh2wvb8U/UA6oRjdVc_I/AAAAAAAAA0o/A4HhHjUoj48/s1600/aclidinum_bromide.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="179" src="http://4.bp.blogspot.com/-cfzGh2wvb8U/UA6oRjdVc_I/AAAAAAAAA0o/A4HhHjUoj48/s320/aclidinum_bromide.png" width="320" /></a></div>
<br />
<br />
<div style="text-align: justify;">
Aclidinum bromide (IUPAC: [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl]2-hydroxy-2,2-dithiophen-2-ylacetate bromide; Canonical smiles (for active quaternary amine): OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c4cccs4)c5cccs5 ; PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11467166&amp;loc=ec_rcs">11467166</a>; Chemspider: <a href="https://www.chemspider.com/Chemical-Structure.9609381.html">9609381</a>; ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1194325">CHEMBL1194325</a>; Standard InChI Key: ASMXXROZKSBQIH-VITNCHFBSA-N) is a synthetic quaternary ammonium compound with one chiral center, a molecular weight of 484.7 Da, 7 hydrogen bond acceptors, 1 hydrogen bond donor, and has an ALogP of 3.4. The compound is therefore fully rule-of-five compliant.</div>
<br />
<div style="text-align: justify;">
Aclidinum bromide is available as a dry powder inhaler and the recommended daily dose is two oral inhalations of 400 mcg. It has an apparent volume of distribution of 300 L following intravenous administration of 400 mcg, and its absolute bioavailability is approximately 6%. The estimated effective half-life of Aclidinum (t<sub>1/2</sub>) is 5 to 8 hours. </div>
<br />
<div style="text-align: justify;">
The major route of metabolism for aclidinum bromide is non-enzymatic and esterases-mediated hydrolysis, being rapidly and extensively converted to its alcohol and dithienylglycolic acid derivatives, neither of which binds to muscarinic receptors - this leads to very low systemic exposure of the active aclidinium species. Excretion of aclidinium bromide is mainly through the urine (54 - 65%) and faeces (20 - 30%), where only 1% is excreted as unchanged aclidinium. The total clearance is approximately 170 L/h after an intravenous dose of  aclidinium bromide in young healthy volunteers.</div>
<br />
<div style="text-align: justify;">
The license holder for Tudorza<sup>TM</sup> Pressair<sup>TM</sup> is <a href="http://www.forestpharm.com/">Forest Pharmaceuticals</a>, and the full prescribing information can be found <a href="http://www.frx.com/pi/tudorza_pi.pdf">here</a>.</div>